Related Experiment Videos

[Disorders of bone metabolism in premature infants]

Insights

Extremely low birth weight infants often develop rickets due to rapid growth and low mineral intake. Certain drugs and phosphate depletion can worsen this bone disease in premature infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Endocrinology
  • Nutritional Science

Context:

  • Extremely low birth weight (ELBW) infants exhibit rapid growth, increasing their risk of nutritional deficiencies.
  • Neonatal rickets, a form of osteopenia, is a significant concern in premature infants.
  • Phosphate depletion can lead to hypercalcemia syndrome preceding bone demineralization in some infants.

Purpose:

  • To discuss the multifactorial etiology of rickets in extremely low birth weight infants.
  • To highlight the role of calciprivic drugs in the development of neonatal rickets.
  • To present findings from experimental animal models and clinical cases, offering a parenteral mineral infusion schedule.

Summary:

  • ELBW infants are susceptible to rickets (osteopenia) due to rapid growth and insufficient calcium and phosphate intake.
  • Adverse effects of drugs like phenytoin, phenobarbital, glucocorticoids, furosemide, and heparin contribute to neonatal rickets.
  • Experimental evidence in animals and clinical reports support the link between mineral imbalances and impaired bone mineralization, with a proposed treatment protocol.

Impact:

  • Informs clinicians about the risk factors and contributing agents for neonatal rickets.
  • Provides a basis for understanding drug-induced bone disease in vulnerable infants.
  • Offers practical guidance for mineral supplementation in affected neonates.

Related Concept Videos